Reach Us +44-3308187254


An Introduction To A Novel Antimalarial Drug ?aretrolane Maleate And Piperaquine Phospahte? | 13350
ISSN: 2167-065X

Clinical Pharmacology & Biopharmaceutics
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

An introduction to a novel antimalarial drug ?aretrolane maleate and piperaquine phospahte?

International Summit on Clinical Pharmacy & Dispensing

Jeetu Gangil

Accepted Abstracts: Clinic Pharmacol Biopharmaceut

DOI: 10.4172/2167-065X.S1.004

Estimated 300-500 million people contract malaria each year, resulting in 1.5-2.7 million deaths annually. According to published research in ?Malaria Journal? (2011), the very low adherence to artemether-lumefantrine raises serious concerns for the malaria control, as this can results in inadequate cure and development antimalarial resistance. The adjudicated published results show 205000 malaria deaths per year in India before age 70. Poor-quality antimalarial drugs lead to drug resistance and inadequate treatment, which pose an urgent threat to vulnerable populations and jeopardise progress and investments in combating malaria. Emergence of artemisinin resistance or tolerance in Plasmodium falciparum on the Thailand-Cambodia border makes protection of the effectiveness of the drug supply imperative. Arterolane Maleate and Pipraquine Phosphate is a fixed dose combination developed for the treatment of acute, uncomplicated P. falciparum malaria in adults, approved in 2011 by Drug Controller General of India. Arterolane Maleate and Pipraquine Phosphate is developed in line with WHO recommendations of using fixed dose combination formulation of a rapid/short acting anti-malarial drug (arterolane) with long-acting anti-malarial partner drug (piperaquine) with complementary effects. Arterolane Maleate and Pipraquine Phosphate provides high clinical efficacy as assessed by ACPR, FCT and PCT. Arterolane Maleate and Pipraquine Phosphate has demonstrated faster median fever clearance time in phase III clinical trial. Arterolane Maleate and Pipraquine Phosphate has achieved high cure rate in Malaria endemic countries with widespread Chloroquine resistance. Arterolane Maleate and Pipraquine Phosphate achieved 28- day PCR corrected ACPR of 97.9% in uncomplicated falciparum Malaria.
Jeetu Gangil has completed his Master of pharmacy at the age of 27 years from Manipal University, Karnataka, India. Jeetu Gangil is working in Innovative Product Team in Ranbaxy Laboratories Pvt ltd, a premier pharmaceutical and research organization. He has published various papers in reputed journals and pharma magazines.